Percutaneous vertebroplasty for pain relief and spinal stabilization

STUDY DESIGN: This was a retrospective review of 47 consecutive patients (1995-1998) in whom percutaneous intraosseous methylmethacrylate cement injection (percutaneous vertebroplasty) was used to treat osteoporotic vertebral compression fractures and spinal column neoplasms. OBJECTIVES: To present initial results regarding pain relief, spinal stabilization, and complications after treatment with percutaneous vertebroplasty. SUMMARY OF BACKGROUND DATA: Percutaneous vertebroplasty was developed in France in the late 1980s. Several European reports have described excellent results for treatment of compression fractures and neoplasms. The procedure was not performed in the United States until 1994. Only a single series of 29 patients treated in the United States has been reported. METHODS: A retrospective review was conducted of 47 consecutive patients with 84 vertebrae treated with percutaneous vertebroplasty. Thirty-eight patients with 70 vertebrae had symptomatic, osteoporotic fractures and had failed medical therapy. Eight patients with 13 vertebrae had primary or metastatic neoplasms. One patient had a hemangioma. Immediate and long-term pain response, spinal stability, and complications were evaluated. RESULTS: Among the 38 patients treated for osteoporotic fractures, 24 (63%) had marked to complete pain relief, 12 (32%) moderate relief and 2 (5%) no significant change. Only 4 of the 8 patients with malignancies had significant pain relief. In 7 of these patients, no further vertebral compression occurred, and spinal canal compromise was prevented. The patient with the hemangioma had no significant pain reduction. Minor complications occurred in 3 (6%) patients. CONCLUSIONS: Percutaneous vertebroplasty provided significant pain relief in a high percentage of patients with osteoporotic fractures. The procedure provided spinal stabilization in patients with malignancies but did not produce consistent pain relief. Complications were minor and infrequent. Percutaneous vertebroplasty is a promising therapy for patients with osteoporotic fractures and for selected vertebral column neoplasms.     

Surgically Controlled, Transpedicular Methyl Methacrylate Vertebroplasty with Fluoroscopic Guidance

Summary  The authors report a series of 13 patients with osteoporotic vertebral fractures treated by transpedicular vertebroplasty. Because of a neurological complication due to posterior leakage of acrylic cement the classical percutaneous approach was converted to an open surgical procedure. The latter allows direct visual control of neural structures and immediate removal of spilled cement, thus eliminating the danger of compressive, chemical and thermal effects of methyl methacrylate on neural elements.  By use of this elegant technique primary stability of fractured vertebras is obtained leading to prompt pain relief in all patients. Surgically controlled vertebroplasty can be used in conjunction with internal fixation. By having studied the different ways of cement escape in their patients, the authors are convinced that surgically controlled vertebroplasty is safer than percutaneous vertebroplasty.     

Modified unilateral transpedicular percutaneous vertebroplasty for treatment of osteoporotic vertebral compression fractures

Objective: To comparatively assess the clinical outcome of modified unilateral percutaneous vertebroplasty for the treatment of osteoporotic vertebral compression fractures. Methods: The clinical outcome and incidence of cement extrusion in a consecutive group of 70 patients at our institution between December 2005 and December 2008 was retrospectively reviewed. Thirty‐five patients were randomly distributed to modified percutaneous vertebroplasty (Group A) and 35 to traditional percutaneous vertebroplasty (Group B). A visual analog scale (VAS) was used on the first post‐operative day and 1 year later to assess the severity of pain before and after vertebroplasty. The incidence of cement extrusion on CT scan was also compared between the two groups. Results: The treatment was successful in all seventy patients. The incidence of cement extrusion was 14.29% (5/35 patients) in group A, and 37.12% (13/35 patients) in group B, this difference being statistically significant (P < 0.05). No patients had serious complications. Complete pain relief was achieved in 50 patients, and significant relief in the other 20 (20/70 patients). There was no statistically significant difference between Groups A and B. Conclusion: Modified percutaneous vertebroplasty enhances the accuracy of cement injection into the center of the vertebral body, increasing the safety of the procedure with no increase in cost. It is a safer and more easily performed technique for treating patients with osteoporotic vertebral compression fractures than traditional percutaneous vertebroplasty.     

经皮椎体成形术治疗椎体病理性压缩骨折

目的　探讨经皮椎体成形 (PercutaneousVertebroplasty ,PVP)在椎体病理性压缩骨折中的治疗效果和适应证的选择。方法　应用PVP对 16例椎体病理性压缩骨折患者进行治疗 ,对其结果进行总结。结果　 16例患者于术后 2 4～ 4 8h疼痛均有不同程度的的减轻或消失。无明显并发症出现。结论　PVP为疼痛性椎体病理性压缩骨折提供了一种有效的微创治疗方法     

Bioceramic vertebral augmentation with a calcium sulphate/hydroxyapatite composite (Cerament™ SpineSupport) in vertebral compression fractures due to osteoporosis

A prospective, non-randomized multicenter study was initiated to study efficacy and safety of a partly resorbable composite of calcium sulphate and hydroxyapatite (Cerament™ SpineSupport), a novel, injectable bioceramic, in osteoporotic patients with vertebral compression fractures during 18-month follow-up. Fifteen patients with low-energy trauma and 1–2 vertebral compression fractures verified by magnetic resonance imaging were recruited to undergo percutaneous bioceramic vertebral augmentation under fluoroscopy. The patients were treated with a highly flowable bioceramic containing calcium sulphate, hydroxyapatite and the non-ionic radiocontrast agent iohexol, with final setting time within 1 h. After the procedure, the patients were allowed to mobilize after 2 h. Pain (VAS), occurrence of remote and adjacent fractures, and Quality of Life (QoL; SF-36 and EQ-5D) was recorded during 18 months. The injected volume of the composite material ranged from 2.8 to 9 mL (mean 4.2 mL). Pre-operative VAS score was mean 70.3 (CI95% ±8.7) with an immediate post-operative pain relief, which was maintained at the 4-week visit (mean 26.4 with CI95% ±16.1) and 8-week visit (mean 18.0 with CI95% ±13.5 pain relief). Eighty percent of the patients demonstrated a clinical improvement. The pain relief was maintained over 18 months and no adjacent fractures were observed. There was a statistically significant improvement of physical components in the QoL assessment. No extra-vertebral leakage or neurological deficits were reported in this series. This first prospective multicenter study on a partly resorbable bioceramic material indicate that fracture healing can be achieved with sustained pain relief over a follow-up period of 18 months in an osteoporotic patient population with vertebral compression fractures.     

经皮穿刺椎体成形术治疗骨质疏松椎体压缩骨折

目的 研究经皮穿刺椎体成形术在治疗疼痛性骨质疏松脊柱压缩骨折中的效用。方法 2年内15例有1－6个月背部、腰部疼痛伴行动障碍需止痛药治疗患（男5人、女10人），年龄58－81岁，经临床、CT及MRI评价为骨质疏松椎体压缩且近期有进展，在CT引导下完成经皮穿刺椎体成形术22例次。治疗效果采用Huskisson止痛视觉评分法评估。结果 13例患（86．7％）在24h内疼痛缓解，12例停用止痛药，余下的2例有轻微疼痛好转（13．3％）。1例患3个月后由于相邻椎体出现新的压缩而疼痛复发，二次治疗好转。结论 经皮穿刺椎体成形术用于骨质疏松椎体压缩是一种微创操作，可以立即缓解疼痛并使患很快恢复运动，是一种有价值的治疗骨质疏松压缩骨折的方法。     

经皮椎体成形术在骨质疏松椎体压缩性骨折治疗中的应用

目的 评估经皮椎体成形术在治疗骨质疏松椎体压缩性骨折中的疗效。方法 对19例22个骨质疏松椎体压缩性骨折患行经皮椎体成形术。结果 所有患经3～12个月的随访，疗效满意，其中优4例(21％)，良12例(63％)，可3例(19％)。术后5例患需阶段性口服药物缓解疼痛，2例骨水泥外溢，但未造成不良后果。结论 经皮椎体成形术是一种微创治疗方法，用于治疗骨质疏松椎体压缩性骨折有明显疗效，可在短时间内解除患痛苦，恢复正常活动。     

Percutaneous vertebroplasty for vertebral compression fracture

BACKGROUND: Percutaneous vertebroplasty has become an option for the treatment of painful osteoporotic compression fractures in patients in whom conservative medical management has failed. AIM: This paper assessed the effectiveness and safety of percutaneous vertebroplasty in patients with focal pain caused by compression vertebral body fractures. MATERIALS AND METHODS: Over a twenty-five-month period 63 patients underwent percutaneous vertebroplasty, and ten of these patients were subsequently retreated, for a total of 73 operations on 93 vertebrae. The patients were affected by osteoporotic compression fractures (n=57) or by benign or malignant infiltrative processes (n=6). All patients were examined at discharge and thereafter to assess the level of pain and investigate possible changes in the quality of life. The mean length of follow-up was 15.2 months. RESULTS: After treatment, almost 90% of patients reported complete disappearance or significant alleviation of the pain. In 7 of 63 of the patient (11%) there were small asymptomatic leakages of cement outside the vertebral body. A substantial number of patients with osteoporosis, 19% of the study population, experienced new fractures following treatment with vertebroplasty. DISCUSSION: Our experience confirms the effectiveness of vertebroplasty to pain caused by vertebral fractures. If the indications are strictly followed, improvement of symptoms is often immediate, allowing the return of mobility, and patient satisfaction with surgery is higher. The use of appropriate systems limits the number of complications.     

Percutaneous vertebroplasty as a treatment for osteoporotic vertebral compression fractures: a systematic review

Percutaneous vertebroplasty has been performed for more than ten years to treat painful osteoporotic vertebral compression fractures. Clinical results have been encouraging, but little is known about the efficacy and safety of this minimally invasive procedure. We therefore performed a systematic review to assess the efficacy and safety of percutaneous vertebroplasty in osteoporotic vertebral compression fractures. A search was conducted using Medline, Embase and The Cochrane Controlled Trials Register. The search yielded fifteen studies, eleven prospective, three retrospective and one controlled trial. Totally 1,136 interventions were performed on 793 patients. Mean pain scores, measured using a 0 to 10 VAS score, improved significantly from 7.8 to 3.1 (−60.3%) immediately after percutaneous vertebroplasty. The short-term complication rate varied between 0.4 and 75.6%. Leakage of cement outside the vertebral body was markedly common, ranging from 3.3 to 75.6%. Although the majority was asymptomatic, a few devastating clinical adverse effects were reported (mean 2.4%). Although percutaneous vertebroplasty is a widely accepted treatment for osteoporotic vertebral fractures, we revealed only a single controlled trial. We conclude that there are insufficient data available to reliably assess efficacy of percutaneous vertebroplasty. The procedure has a low rate of clinical complications, but potential complications can be devastating. In the future, assessing the efficacy of percutaneous vertebroplasty requires controlled trials with long-term follow-up.     

应用经皮椎体成形术治疗骨质疏松性椎体骨折的研究

目的 探讨椎体成形术（PVP）在治疗骨质疏松性椎体压缩性骨折（OVCF）中的作用.方法 31例骨质疏松性压缩性骨折患者接受了椎体成形术,患者均有背部疼痛.在X线透视引导下,经单侧或双侧椎弓根入路行PVP,每个椎体注入骨水泥量为3～8 ml,平均6.0 ml,完成46个椎体成形术.术后患者随访1～18个月.结果 31例中绝大多数患者术后6 h～2 d疼痛明显缓解或消失.结论 椎体成形术为骨质疏松压缩性骨折经保守治疗无效患者提供了一种安全、微创、有效的治疗方法.     

Balloon kyphoplasty versus percutaneous vertebroplasty for osteoporotic vertebral body compression fractures: clinical and radiological outcomes

BACKGROUND CONTEXTOsteoporotic vertebral body compression fracture are the commonest fractures amongst the other osteoporotic fracture sites. These fragility fractures are the result of low energy mechanical forces that that would not ordinarily result in fracture. Percutaneous vertebroplasty and balloon kyphoplasty has been widely used as minimally invasive procedures to treat painful vertebral compression fractures.PURPOSEAim of the present study was to evaluate radiological, clinical and functional outcome of patients with osteoporotic vertebral body fractures treated with Balloon Kyphoplasty and Vertebroplasty.STUDY DESIGNProspective cohort studyPATIENT SAMPLE40 patients (Male:15, Female: 25) with average age of 56 +/- 8 years diagnosed with osteoporotic vertebral body compression fracture on clinical and radiological evaluation with no neurological deficit and no other associated fractures were included.OUTCOME MEASURESOperative time, cost for the procedure, gain in vertebral body height, reduction in pain, ability to perform daily routine activities, risk of cement leakage and any other systemic complications were evaluated and compared in both the study groups.METHODSAll the patients underwent conventional Xray, MRI (to rule out acute from chronic fracture, to check compromise of spinal canal and calculate collapse in vertebral body height), Visual analog scaling for severity of pain and difficulty in daily routine activities by Oswestry disability index preoperatively. Post operative clinal, functional, radiological outcome and complications were compared in patients treated with percutaneous vertebroplasty and balloon kyphoplasty.RESULTThere was significant difference in intraoperative time period and procedure cost for the patients treated with Vertebroplasty(50.75min, 25k) in comparison to balloon kyphoplasty (71.95, 50k) with p value being < .001There was significant difference between preoperative and postoperative study parameters in both the study groups but there was no significant difference in post operative study parameters amongst both the study groups with p values >.05 for different parameters, 0.381(Gain in vertebral height), 0.108 (pain relief), 0.846(Oswestry disability index) and 0.197(risk of cement leakage)CONCLUSIONOur study suggested that percutaneous vertebroplasty requires less operative time and is more economical than balloon kyphoplasty. Increase in intraoperative time increases the risk of infection. Though the cases of Intraoperative operative cement leakage were more in percutaneous vertebroplasty but is was not significant. However the final radiological, clinical, functional outcome and overall complications were found to be similar in both the groups. Balloon kyphoplasty provided no added benefit over percutaneous vertebroplasty. A study with larger sample size will be needed to warrant one surgical procedure superior to other in the treatment of osteoporotic vertebral body compression fracture.     

Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty.

BACKGROUND CONTEXT: Osteoporotic vertebral compression fractures (VCFs) are being increasingly treated with minimally invasive bone augmentation techniques such as kyphoplasty and vertebroplasty. Both are reported to be an effective means of pain relief; however, there may be an increased risk of developing subsequent VCFs after such procedures. PURPOSE: The purpose of this study was to compare the effectiveness and complication profile of kyphoplasty and vertebroplasty in a single patient series. STUDY DESIGN/SETTING: A clinical series of 36 patients with VCFs treated by vertebral augmentation procedures was retrospectively analyzed for surgical approach, volume of cement injected, cement extravasation (symptomatic and asymptomatic), the occurrence of subsequent adjacent level fracture, and pain relief. PATIENT SAMPLE: Thirty-six patients with 46 VCFs underwent either kyphoplasty or vertebroplasty after failing conservative therapy. The mean patient age was not significantly different between the kyphoplasty group (70; range, 46-83) and vertebroplasty group (72; range, 38-90) (p=.438). OUTCOME MEASURES: Outcomes were assessed by using self-report measures (a comparative pain rating scale) and physiologic measures (pre- and postoperative radiographs). METHODS: Thirty-six patients with VCFs underwent 46 augmentation procedures (17 patients had 20 fractures treated via kyphoplasty, and 19 patients had 26 fractures treated via vertebroplasty). Seventeen patients in this series underwent kyphoplasty using standard techniques involving bone void creation with balloon tamps, followed by cement injection. Nineteen patients underwent a percutaneous vertebroplasty procedure using a novel cannulated, fenestrated bone tap developed to direct cement anteriorly into the vertebral body to avoid backflow of cement onto neural elements. RESULTS: Pain improvement was seen in >90% of patients in both groups. Mean cement injection per vertebral body was 4.65 mL and 3.78 mL for the kyphoplasty and vertebroplasty groups, respectively (p=.014). Ninety-five percent of the kyphoplasty procedures were performed bilaterally, whereas only 19% of the vertebroplasty procedures required bilateral augmentation (p<.001). There was no cement extravasation resulting in radiculopathy, or myelopathy in either group. Asymptomatic cement extravasation was seen in 5 of 46 (11%) of the total series (3/20 [15%] and 2/26 [7.7%] of kyphoplasty and vertebroplasty, respectively) (p=.696). Within a 3-month period, there were 5 new adjacent level fractures seen in 3 patients who underwent a kyphoplasty procedure (5/20 [25%]) and none in the vertebroplasty group (p<.05). CONCLUSIONS: Vertebroplasty appears to offer a comparable rate of postoperative pain relief as kyphoplasty while using less bone cement more often via a unilateral approach and without the attendant risk of adjacent level fracture.     

垫枕法联合经皮椎体成形术治疗老年骨质疏松胸腰椎压缩性骨折

目的：观察垫枕法联合经皮椎体成形术治疗老年骨质疏松胸腰椎压缩性骨折的效果。方法：选择老年骨质疏松胸腰椎压缩性骨折患者 40 例，予垫枕法联合经皮椎体成形术治疗，并观察患者术前及术后 1 个月在疼痛缓解、伤椎前缘高度、后凸畸形改善的情况。 结果：40 例患者术前疼痛视觉模拟评分（visual analogue scale，VAS）（6.76±1.16）、伤椎前缘高度（16.38±2.26）mm 及 Cobb 角（22.17±3.46）?，术后 1 个月 VAS 评分（2.34±0.73）、伤体前缘高度（28.45±6.46）mm及 Cobb 角（8.43±4.34）?，术后 1 个月患者在疼痛缓解、伤椎前缘高度、后凸畸形改善等方面较术前有明显区别（P<0.05）。结论：老年骨质疏松胸腰椎压缩性骨折经垫枕法联合经皮椎体成形术治疗，可明显减轻患者疼痛，改善后凸畸形。     

经皮椎体成型术在骨质疏松性椎体压缩骨折中的临床应用分析

目的探讨经皮椎体成型术在骨质疏松性椎体压缩骨折中的临床疗效。方法对笔者所在医院就诊的18例患者采用经皮椎体成型术治疗骨质疏松性胸腰椎压缩骨折,手术在C臂机监测下,经皮向椎体内穿刺并注入骨水泥,并对患者术后椎体疼痛症状及椎体前缘高度进行分析。结果术后全部患者获得随访,随访时间1～18个月,平均11个月,患者腰背部疼痛明显好转,椎体前缘高度无明显继发丢失,椎体后凸角度无明显增大。结论经皮椎体成型术治疗骨质疏松性椎体压缩骨折安全有效,疗效满意。     

Percutaneous vertebroplasty for symptomatic osteoporotic vertebral compression fracture adjacent to lumbar instrumented circumferential fusion

The purpose of this study was to evaluate the efficacy and safety of percutaneous vertebroplasty for patients with symptomatic osteoporotic vertebral compression fractures adjacent to lumbar instrumented circumferential fusion. Between January 2005 and June 2010, eighteen patients in the authors' institution with lumbar instrumented circumferential fusion had adjacent symptomatic osteoporotic vertebral compression fractures. The patients received percutaneous vertebroplasty using polymethylmethacrylate bone cement augmentation. Radiographs and magnetic resonance imaging were used. The visual analog pain scale and modified Brodsky's criteria were used to compare clinical outcomes pre- and postoperatively. Minimum follow-up was 18 months. Dual-energy x-ray absorptiometry scan confirmed osteoporosis in all patients. The average interval between fusion surgery and sustaining osteoporotic vertebral compression fractures was 24.8 months. The average interval between sustaining osteoporotic vertebral compression fractures and undergoing percutaneous vertebroplasty was 49.3 days. One-level percutaneous vertebroplasty was performed in 13 patients, and 2 levels were performed in 5 patients. The patients' visual analog pain scale scores improved by an average of 53 points postoperatively. Fifteen patients returned to preinjury activities of daily living. The average restoration of the fractured vertebral body height was 12.1%. No major surgery-related complications, occurred except asymptomatic cement leakage in 3 patients. Elderly patients undergoing lumbar instrumented fusion surgery should be aware of the possibility of adjacent vertebral compression fractures. Percutaneous vertebroplasty is a minimally invasive and effective procedure to treat such adjacent segment disease.     

经皮椎体成形术治疗以脊柱源性腹痛为主要症状的骨质疏松性椎体压缩性骨折

目的:分析经皮椎体成形术对以脊柱源性腹痛为主要症状的骨质疏松性椎体压缩性骨折的疗效。方法:回顾性分析2015年1月至2021年1月就诊的37例骨质疏松性椎体压缩性骨折患者,患者均以脊柱源性腹痛为主要症状,根据治疗方法不同分为手术组(21例)和保守组(16例)。手术组患者采用经皮椎体成形术治疗,男7例,女14例,年龄(75.95±6.84)岁,病程(5.26±3.79) d。保守组患者采用非手术治疗,男5例,女11例,年龄(75.50±8.07)岁,病程(4.28±3.42) d。两组患者术前主要表现为腹痛、腹胀或便秘,均无明显胸腰背部疼痛症状,经胸腰椎MRI确诊为新鲜的骨质疏松性椎体压缩性骨折,术后记录其腹痛视觉模拟评分(visual analogue scale,VAS),简明健康状况调查表(medical outcomes study short form-36,SF-36)评分,治疗后排便时间等。结果:37例患者均获得随访,随访时间手术组(14.90±14.11)个月,保守组(21.42±17.53)个月。两组患者治疗前基线资料比较差异无统计学意义(P>0.05)。相较于治疗前,手术组治疗后各时段VAS、保守组治疗后1个月VAS、两组治疗后3个月SF-36中8个维度评分均较术前明显改善(P<0.05);保守组治疗后3 d VAS与术前比较差异无统计学意义(P>0.05)。治疗前1 d 的VAS、SF-36中8个维度评分组间比较差异无统计学意义(P>0.05),治疗后3 d 的VAS、治疗后3个月生活活力及社会功能维度评分、治疗后排便时间手术组均优于保守组(P<0.05),其余指标差异无统计学意义(P>0.05)。手术组患者切口愈合良好,两组患者均无严重并发症发生。结论:经皮椎体成形术是治疗以脊柱源性腹痛为主要症状的骨质疏松性椎体压缩性骨折有效的方法,与保守治疗相比,在早期缓解腹痛及便秘症状、恢复生活活力及社会功能方面更有优势。     

经皮穿刺椎体成型术治疗老年性骨质疏松性椎体压缩骨折的疗效分析

目的探讨经皮穿刺椎体成型术(perutaneous vertebroplasty,PVP)治疗老年性骨质疏松性椎体压缩骨折(VCF)的近期疗效。方法应用经皮穿刺椎体成型术治疗23例老年性骨质疏松椎体压缩骨折,共28个椎体。CT检查明确病椎椎体后壁的完整,应用C型臂X光机手术前和手术中定位,采用经单侧椎弓根手术入路,平均骨水泥注射量2～4ml左右。术前后应用国际通用术前疼痛目测分级(VAS)评分。结果23例患者28个椎体操作全部成功,成功率100%。术后3d疼痛开始缓解15例;术后1个月疼痛完全缓解18例(1823),显著缓解5例(523)。VAS评分平均2.01分,与术前比较有显著性差异(P<0.001)。术后1年随访,患者完全满意16例,满意5例,较满意2例。术后1年疼痛VAS评分平均2.13分;与术后1个月比较无显著性差异(P>0.05)。结论PVP是一种治疗骨质疏松椎体骨折的微创手术,能有效缓解骨质疏松性椎体骨折引起的疼痛,维持椎体稳定性,是一种有价值治疗骨质疏松性骨折的方法。     

Treatment of pain from osteoporotic vertebral collapse by percutaneous PMMA vertebroplasty

Summary Background. Vertebral compression fractures are common complications in advanced osteoporosis. In general, this disease of the elderly patient is characterized by severe local back pain. Pathophysiologically, bony instability triggers local pain during body movement. Serious pain immobilizes the patients and forces them to bed rest. As a result, complications like thrombosis or pneumonia occur. Invasive treatment with surgical instrumentation for vertebral stabilization is not indicated in elderly patients especially with additional diseases.The purpose of this study was to test the hypothesis that percutaneous polymethylmethacrylate (PMMA) vertebroplasty significantly reduces pain due to vertebral collapse in osteoporotic patients and improves quality of life.Methods. A total of 38 patients with osteoporotic vertebral compression fractures of the thoracic and lumbar spine were treated by PMMA vertebroplasty. After admission, before discharge from the hospital, six weeks, half a year and one year later patients answered the Oswestry Low Back Pain Disability (OLBPD) Questionnaire for assessment of treatment related change in disability. In all patients percutaneous vertebroplasty was performed under local anesthesia.Findings. A total of 92% of patients reported a significant pain reduction immediately after treatment. Also one year after vertebroplasty pain remained significantly reduced. Vertebroplasty was highly beneficial for patients with pain related to local instability of the spine. Extravasation of PMMA beyond the vertebral margins was observed in 26% of the cases. No treatment related clinical or neurological complications were noticed.Interpretation. PMMA vertebroplasty is a useful and safe method of pain relief which rapidly regains quality of life for patients with osteoporotic vertebral compression.     

陈旧性与新鲜性压缩骨折行椎体成形术的临床对比研究

目的回顾性对比研究陈旧性与新鲜性椎体压缩性骨折行经经皮椎体成形术（percutaneouss vertebra plasty,PVP）后的临床效果。方法对24例老年骨质疏松性胸腰椎压缩性骨折患者行PVP治疗,将研究对象按陈旧性骨折和新鲜性骨折分为2组,分别拍摄2组术前、术后标准正侧位X线片,从而对骨折椎体高度的恢复、后凸畸形的矫正及疼痛视觉模拟量表（visual analogue scale,VAS）评分进行研究对比。结果所有患者术后平均随访6个月,无严重并发症发生。2组患者术后疼痛缓解且恢复良好,均恢复日常活动能力。但陈旧性压缩性骨折患者术后椎体高度恢复和后凸畸形的矫正程度均不如新鲜性骨折患者。结论 PVP术操作简单、创伤小,对于骨质疏松性椎体压缩性骨折的治疗效果明显,尤其对新鲜骨折效果显著,且对于缓解陈旧性骨折疼痛症状也有良好效果。